20 results about "Leukocyte Counts" patented technology

The invention belongs to the field of pesticide poisoning prognosis, and particularly discloses a method for establishing an acute diquat pesticide poisoning prediction death risk index, which comprises the following steps: collecting data; establishing a death risk index model based on demographic characteristics and blood routine test results; and carrying out model training, internal verification and external verification. The death risk index provided by the invention comprehensively considers age, diquat blood concentration, leukocyte count and glutamic oxalacetic transaminase concentration, and aims to accurately evaluate the death risk of acute diquat pesticide poisoning patients in an index form. Through deep analysis of large-scale clinical data, the death risk index of the invention not only has scientificity and accuracy on the data level, but also can play an important role in clinical practice, can be applied to construction of acute diquat pesticide poisoning death risk prediction terminal equipment, helps medical teams to distribute medical resources more reasonably, and has a good application prospect. High-risk patients are preferentially processed, so that the overall treatment effect and the survival opportunity of the patients are improved.

Provided is a subject measurement device capable of efficiently performing a subject inspection service including an inspection of malaria infection. A subject measurement device for measuring a subject collected from a subject includes: a measurement unit for preparing a measurement sample from the subject and a reagent and detecting at least an optical signal corresponding to cells in the measurement sample; and an analysis means for analyzing the cells on the basis of the measurement of the subject by the measurement means. The measurement unit is capable of selectively performing a plurality of measurement operations on a subject. The plurality of measurement operations include: a first measurement operation in which a subject is measured using a first reagent containing a first fluorescent dye for staining white blood cells for classification of white blood cells, and a second measurement operation in which the subject is measured using a second reagent containing a second fluorescent dye for staining white blood cells for classification of white blood cells; a second measurement operation in which the subject is measured using a second reagent containing a second fluorescent dye that stains cells suspected of being infected with malaria; and a third measurement operation in which the subject is measured using the first reagent and the second reagent.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The object is to provide a blood processing filter having excellent leukocyte removal rate and filtration time (filtration speed). The aforementioned problems can be solved by the following blood filter. A blood processing filter, comprising: a container having an inlet and an outlet for blood, and a filter material arranged between the inlet and the outlet in the aforementioned container, the aforementioned filter material comprising a filter layer, the aforementioned filter layer comprising a non-woven fabric, the fibers of the aforementioned non-woven fabric having an orientation degree X in the X-axis plane direction of the aforementioned filter layer, and an orientation degree Y in the Y-axis plane direction orthogonal to the aforementioned X-axis plane direction, and the maximum value of the ratio of the aforementioned orientation degree X to the aforementioned orientation degree Y (orientation degree X / orientation degree Y) is greater than 1.2.

The present application provides a blood separation method for a sampling needle and a blood cell analyzer, the method comprising: collecting a blood sample through a sampling needle, the blood sample being distributed into multiple sections in sequence in the sampling needle; discarding the first section of the blood sample near the needle head in the sampling needle; allocating a first preset ratio of the blood sample near the first section of the blood sample in the sampling needle to a reticulocyte counting section; allocating a second preset ratio of the blood sample located in the middle section of the sampling needle to a white blood cell counting section and a hemoglobin / red blood cell counting section; and allocating a third preset ratio of the blood sample near the end of the sampling needle to a white blood cell classification counting section. The blood separation method for a sampling needle and the blood cell analyzer of the present application can allocate multiple blood sections in the sampling needle to appropriate counting sections, thereby improving the measurement performance of the blood cell analyzer.

The present disclosure describes a method and system for screening for sepsis or septic shock in a patient, and a method for ruling out sepsis or septic shock in a patient, using white blood cell count (WBC), monocyte cell population parameters, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in a blood sample from the patient. In one aspect, the present disclosure describes a method for screening for sepsis or septic shock in a patient.

The invention relates to the technical field of medical detection, in particular to a brain tumor postoperative infection evaluation model based on a cerebrospinal fluid (CSF) test index, which is used for rapidly diagnosing intracranial infection and predicting patient prognosis. A brain tumor postoperative infection assessment model construction method is characterized by comprising the following steps: (1) integrating cerebrospinal fluid total protein C-TP, glucose C-Glu, chloride C-Cl-, leukocyte count C-leukocytes, the number of multinucleated cells C-multinucleated, the proportion of multinucleated cells C-multinucleated%, color, turbidity and Pandy test results through Fisher discriminant analysis, and generating a discriminant function; and (2) prognosis prediction: analyzing the correlation between the cerebrospinal fluid parameter index level and the infection control time. By analyzing 389 patient data, 9 CSF parameters with significant differences are screened out, a model is constructed, and the clinical value of the model is verified.

Systems and methods for non-invasive leukocyte counting in serous bodily fluids. The system (100) includes () an ultrasound device (110) that generates ultrasound images (102) from a body (104) or a sample (106) in a scanning direction (x) at a configurable spatial resolution, and an image processing unit (120) that receives first ultrasound images (412) generated by the ultrasound device (110) at a first spatial resolution, and, for each first ultrasound image (412), generates a second ultrasound image (412) at a second spatial resolution, the method further includes determining a region (422) corresponding to the serous body fluid, determining a target focal point (432) in the region (422), and receiving at least one second ultrasound image (442) generated by the ultrasound device (110) focused on the target focal point (432) in the scanning direction (x) at a second spatial resolution higher than the first spatial resolution. The image processing unit (120) predicts the concentration (130) of leukocytes from the at least one second ultrasound image (442) using an artificial neural network (2100) trained with images having assigned reference truth value concentrations.

1. Name of the design product: Graphical user interface for electronic equipment. 2. Purpose of this design product: for use in an electronic device. 3. The design key points of this appearance design product are: the graphical user interface content. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The electronic equipment is of conventional design, and the rear view, left view, right view, top view and bottom view are omitted. 6.Purpose of the graphical user interface: used for the interpretation of medical technical reports and to provide auxiliary decision-making reminders for report indicators in clinical test report review scenarios. 7. Description of the changing status of the graphical user interface: In the main view, click "Result" at the bottom of the white blood cell count to switch to the changing status diagram 1; click "Impact Analysis" in the changing status diagram 1 to switch to the changing status diagram 2; click "Change Trend" in the changing status diagram 2 to switch to the changing status diagram 3; click "AI Intelligent Analysis" in the changing status diagram 3 to switch to the changing status diagram 4. 8. Other situations that require explanation: The overlay area is the content screen area; X indicates replaceable text content.

The invention provides a model for predicting the risk of allergic reaction of a Wilson disease patient during copper expelling treatment, and belongs to the crossing field of clinical medicine and biological information technology. The risk prediction model comprises: an input module receiving patient parameter indexes composed of a sodium dimercaptopropanesulfonate injection dosage, a severe adverse drug reaction, a drug allergy history, a neutrophil count, a lymphocyte count, a ratio of neutrophil to lymphocyte, a ratio of platelets to lymphocyte, a leukocyte count, a urine copper level and a platelet count; the processing module is connected with the input module and is used for calculating the score and prediction probability of the allergic reaction during copper expelling treatment based on the parameter indexes of the patient; and the output module is connected with the processing module, and outputs the allergic reaction risk probability obtained by the risk prediction model during the copper expelling treatment of the Wilson disease patient. The risk prediction model can be conveniently used for early recognition and risk prediction of anaphylaxis of a Wilson disease patient during copper expelling treatment.

The present invention relates to an isolated targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and a pharmaceutically active substance, label or pharmaceutically active substance and label, for use in a method of treatment or diagnosis of glioma.

The invention discloses an application of alpha-ketoglutaric acid in diagnosis and treatment of acute pancreatitis, diagnosis of acute pancreatitis is realized by detecting the concentration of alpha-ketoglutaric acid in serum or plasma of a detected person, and the invention also provides an application of alpha-ketoglutaric acid in preparation of a diagnostic reagent for monitoring the condition of acute pancreatitis. By dynamically detecting the concentration change of alpha-ketoglutaric acid in serum or plasma of a patient, the real-time monitoring of the illness state is realized. The invention discloses the specific accumulation of the endogenous alpha-ketoglutaric acid level in the serum of a patient with acute pancreatitis for the first time, and the endogenous alpha-ketoglutaric acid level is remarkably positively correlated with disease severity indexes (such as amylase and leukocyte count); the invention provides a simple, convenient and effective serological biomarker for early and accurate diagnosis and illness monitoring of acute pancreatitis, and provides a novel treatment strategy with strong targeting property.

The invention provides a method and a device for predicting bonding between a protein fragment and a major histocompatibility complex (MHC). The method for predicting the bonding of the peer-MHC comprises the following steps of: selecting the peer-MHC; a peptide sequence and an MHC sequence are obtained. According to the peptide sequence and the MHC sequence, at least one Protein Data Bank, PDB is obtained by at least one Protein Data Bank prediction model. Obtaining at least one structure combination pointer by at least one structure combination simulation tool according to the protein structure file; a human leukocyte antigen (HLA) type corresponding to a peptide sequence and a corresponding MHC sequence is obtained by using a human leukocyte antigen (MHC) sequence as an antigen sequence of a human leukocyte antigen (HLA). Obtaining at least one affinity index by at least one affinity analysis model according to the peptide sequence and the HLA type; the input structure combines the pointer and the affinity pointer to a machine learning model to obtain an integrated score.

The invention discloses a drug carrier with a blood-brain barrier crossing characteristic, which comprises an extracellular vesicle, and the surface of the extracellular vesicle is provided with a human leukocyte antigen-G antibody. Wherein the drug carrier can be further used as a pharmaceutical composition to achieve the effects of promoting the apoptosis of brain tumor cells, inhibiting the growth of the brain tumor cells, or reducing the expression of O6-methylguanine-DNA (Deoxyribose Nucleic Acid) methylated metastasis (O6-MGMT) in the brain tumor cells, so as to achieve the effect of treating glioblastoma multiforme (GBM).

The invention relates to the field of hepatobiliary postoperative infection risk grading early warning, in particular to a hepatobiliary postoperative infection risk grading early warning method based on clinical parameters. The method comprises the steps that original clinical parameters are collected and preprocessed, and preprocessed standardized clinical parameters are obtained; a clinical basic weight is introduced, and based on the preprocessed standardized clinical parameters, an infection risk score is obtained through calculation by applying a multi-dimensional distribution mapping algorithm; and risk grades are divided based on infection risk scores, a dynamic weighting mechanism emphasizing effective updating is introduced, and clinical basic weights are dynamically updated. The problems that a traditional hepatobiliary postoperative infection risk assessment method neglects complex high-order interaction and non-linear correlation among indexes such as body temperature, leukocyte count, procalcitonin and C-reactive protein, cannot adjust parameter weights in real time according to dynamic changes of postoperative illness states of patients, lacks a clear risk grading rule and is poor in risk assessment accuracy are solved. And the engineering application value is limited.

The invention relates to the technical field of leukocyte counting, in particular to a leukocyte classified counting device and method for acute respiratory infection patients. The method comprises the following steps: screening leukocytes according to manifestation of cell membrane fluorescence and manifestation component types to obtain leukocytes in a single-cell suspension sample; dividing a plurality of periodic groups according to the similarity degree of the fluorescence intensity of the interleukin nuclear DNA; further analyzing scattered light characteristics of cells in a single cell population in a same-period state, and dividing cell subpopulations; performing corresponding one-to-one combination on the cell subgroups of every two cycle groups according to differences among different components to obtain leukocyte classification of the single-cell suspension sample; according to the cell number distribution of the classification results of the multiple single-cell suspension samples, final classification counting is achieved. According to the method, classification division and combination of the white blood cells in different growth states are combined, so that the accuracy of classification division of the white blood cells is improved, and a more accurate white blood cell classification counting result for acute respiratory infection patients is obtained.

This invention discloses a method and system for early warning of pediatric sepsis risk based on leukocyte dynamic trajectory. The method includes: acquiring time-series leukocyte count data of a target pediatric patient for N consecutive days after admission or diagnosis of sepsis, forming a raw data sequence; preprocessing the raw data sequence to eliminate baseline differences between individuals; inputting the preprocessed data sequence into a pre-trained leukocyte dynamic trajectory classification model to output the probability of the target pediatric patient belonging to each category, and determining the category with the highest probability as the current trajectory category of the target pediatric patient; mapping the current trajectory category to the corresponding sepsis risk level according to a preset trajectory category-risk level mapping rule; and determining whether to generate early warning information based on the sepsis risk level. This invention can automatically analyze continuous leukocyte count data after patient admission, identify its characteristic dynamic change trajectory, automatically determine the risk level based on the trajectory pattern, and issue timely early warnings.

The application discloses a synchronous detection device for immunological detection and white blood cell counting and a detection method thereof, and belongs to the technical field of analysis and detection. The device provided by the application can automatically and synchronously complete immunological index detection and white blood cell counting by only dropping a blood sample to be detected into a sample adding port of a detection card, and is simple to operate and high in detection efficiency. The device is simple in structure, convenient to carry, and can be applied to bedside detection, grass-roots diagnosis and treatment, and detection of the illness of wounded and sick people in special environments. The detection method using the device has a long time window and is not disturbed by impurities, and thus the detection accuracy is improved.

The invention provides a micro-fluidic chip for realizing classified counting of white blood cells and inflammation detection and a use method, the micro-fluidic chip comprises a sample adding port, a sample storage pool, a hemolytic agent liquid bag, a diluent liquid bag and a mixing pool, the sample adding port is connected with the hemolytic agent liquid bag through a channel, the sample adding port is connected with the sample storage pool through a channel, and the diluent liquid bag is connected with the mixing pool through a channel. The mixing pool is connected with the sample storage pool through a channel, the diluent sac is connected with the mixing pool through a channel, the mixing pool is connected with the probe pool through a channel, the air sac I is connected with the probe pool through a channel, and the probe pool is connected with the SAA antibody pool, the CRP antibody pool and the leucocyte sample pool through three channels. The SAA antibody pool is connected with the SAA detection pool, the air bag II is connected with the SAA detection pool through a channel, the CRP antibody pool is connected with the CRP detection pool, and the air bag III is connected with the CRP detection pool through a channel. According to the invention, blood routine examination and CRP and SAA verification index detection can be realized at the same time.

Some embodiments of the present disclosure provide a method for comparing gene consistency, comprising comparing the consistency between a sample to be tested and human leukocyte antigen genes, short tandem repeat sequences, and killer cell immunoglobulin-like receptor genes of a target gene group, and when the human leukocyte antigen gene comparison result, the short tandem repeat sequence comparison result and the killer cell immunoglobulin receptor gene comparison result are consistent, judging that the target gene group is consistent with the to-be-detected gene group of the to-be-detected sample. Some embodiments of the present disclosure also provide a method for determining the consistency of source individuals of a plurality of samples. By comparing triple highly polymorphic genes, the to-be-detected sample and the target sample are encrypted by the gene coded lock, so that the probability of taking wrong to-be-detected samples is reduced.